Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.52 |
| ▸ | GSK3B | P49841 | 10/20 | 0.47 |
| ▸ | CYBB | P04839 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KLF10 | Q13118 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017193 | 1.00 | PKM (0.62) | PKMPTPN1GSK3BCYBBHTT | |
| SCHEMBL10477831 | 0.86 | PTPN1 (0.48) | PKMPTPN1GSK3BHTTALDH1A1 | |
| SCHEMBL8772648 | 0.85 | HSP90AA1 (0.57) | PKMPTPN1GSK3BHTTALDH1A1 | |
| SCHEMBL15394749 | 0.81 | PKM (0.62) | PKMPTPN1CYBBHTTALDH1A1 | |
| SCHEMBL14357335 | 0.81 | PKM (0.68) | PKMPTPN1CYBBHTTALDH1A1 | |
| SCHEMBL27594954 | 0.81 | PKM (0.62) | PKMPTPN1CYBBHTTALDH1A1 | |
| SCHEMBL4344454 | 0.81 | HTT (0.48) | PKMPTPN1GSK3BHTTALDH1A1 | |
| SCHEMBL8343669 | 0.80 | PTPN1 (0.59) | PTPN1GSK3BPOLB | |
| SCHEMBL11551883 | 0.80 | GSK3B (0.49) | PKMPTPN1GSK3BHTTALDH1A1 | |
| SCHEMBL10462920 | 0.80 | PTPN1 (0.50) | PKMPTPN1GSK3BHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109574817-B | Method for synthesizing vilanterol intermediate in mixed solvent | 安徽德信佳生物医药有限公司 | 2021-09-14 | — | — | CN | claimed |
| CN-114409552-B | Levorotatory sand hydrochloride preparation method of butylamine alcohol | 广州博济生物医药科技园有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115286521-B | Synthesis method of levosalbutamol hydrochloride | 上海医药集团(本溪)北方药业有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-115215756-B | Organic fluorescent probe with endoplasmic reticulum targeting function, and preparation method and application thereof | 华南理工大学 | 2023-10-27 | — | — | CN | disclosed |
| WO-2023097696-A1 | METHOD FOR SYNTHESIZING (1R)-1-(2,2-DIMETHYL-4H-1,3-BENZODIOXIN-6-YL)-2-NITROETHANOL | 广东莱佛士制药技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023097678-A1 | METHOD FOR SYNTHESIZING (R)-5-(2,2-DIMETHYL-4H-BENZO[D][1,3]DIOXIN-6-YL)OXAZOLIDIN-2-ONE | 广东莱佛士制药技术有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-115286521-A | Synthesis method of levosalbutamol hydrochloride | 上海医药集团(本溪)北方药业有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115215756-A | Organic fluorescent probe with endoplasmic reticulum targeting function and preparation method and application thereof | 华南理工大学 | 2022-10-21 | — | — | CN | disclosed |
| CN-114409552-A | Preparation method of levalbuterol hydrochloride | 广州博济生物医药科技园有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-109574817-B | Method for synthesizing vilanterol intermediate in mixed solvent | 安徽德信佳生物医药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-5066678-A | PHENETHANDAMINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | GLAXO GROUP LIMITED (GB) | 1991-11-19 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
| US-4990505-A | Treating asthma, bronchitis; adrenergic stimulants | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
| EP-0401966-A1 | Phenethanolamine derivatives, processes for their preparation and pharmaceutical compositions containing them | GLAXO GROUP LIMITED (GB) | 1990-12-12 | — | — | EP | disclosed |
| US-4963564-A | ADRENERGIC STIMULANTS | GLAXO GROUP LTD. (GB) | 1990-10-16 | — | — | US | disclosed |
| EP-0303465-A2 | Phenethanolamine derivatives | GLAXO GROUP LIMITED (GB) | 1989-02-15 | — | — | EP | disclosed |
| EP-0219350-A2 | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1987-04-22 | — | — | EP | disclosed |
| US-4154761-A | B2-ADRENORECEPTOR STIMULANTS, A-/ARYLAMINO-ALKYLAMINOETHYL/-4-HYDROXY-1,3-BENZENE-DIMETHANOL | ALLEN & HANBURYS LIMITED (GB) | 1979-05-15 | — | — | US | disclosed |